Skinvisible, Inc. (OTCBB: SKVI) Skinvisible Product Line Broad, Diverse and Made to Sell

Written by StockGuru on July 26, 2009

Dear Members,

I wanted to address a couple of the questions on SKVI. One of the key things I am being asked is about the diversity of the company. I wanted to make sure you see that Skinvisible is a much wider based company than simply its formulation that I think will see huge demand, DermSafe that can product against H1N1 as a hand sanitizer for up to four hours. I think that is HUGE – however – let’s look at the latest 10Q to see the variety of products they are invovled with. FYI, this is a growing and changing company.

BELOW IS QUOTED FROM THE 10-Q DATED MAY 14, 2009:

Skinvisible's Formulas with
Invisicare:
         ACTIVE INGREDIENT                TYPE        Availability            Patent
Acne
 Adapalene Cream & Gel (0.1% & 0.3%)              Rx           yes*                     pending
Clindamycin Hydrochloride Cream (1%)              Rx           yes*                     pending
          Retinoic Acid Cream (0.1%)              Rx           yes*                     pending
       Benzoyl Peroxide (2.5%) Cream        Rx / OTC In development                     pending
Actinic Keratosis
           Imiquimod Lotion (2%, 3%)              Rx            yes                     pending
Analgesics
Topical Spray with Menthol (6% & 8%)             OTC            yes                  technology
  Topical Roll-On with Menthol (6% &
                                 8%)             OTC            yes                  technology
 Topical Cream with Salicylate (10%)             OTC            yes                  technology
Anti-Aging
                Retinol Cream (0.3%)        Cosmetic            yes                  technology
Anti-Fungal
         Terbinafine Cream, Gel (1%)             OTC            yes                     pending
                Naftifine Cream (1%)              Rx            yes                     pending
Naftifine (1%) & Hydrocortisone (1%)
                               Cream              Rx            yes                     pending
             Clotrimazole Cream (1%)             OTC            yes                     pending
Anti-Inflammatory
           Hydrocortisone Cream (1%)             OTC            yes                  technology
                  Triamcinolone (1%)              Rx            yes                  technology
        Triamcinolone Acetonide (1%)              Rx            yes                  technology
     Clobetasole Proprionate (0.05%)              Rx    in-progress                  technology
                  Betamethasone (1%)              Rx            yes                  technology
Antimicrobial Lotions
          Triclosan Lotion (1%) with                           yes*
                         Nonoxynol-9             OTC                                    granted
  Triclosan Lotion (1%) with Tomadol                           yes*
                                 901             OTC                                    granted
Benzalkonium Chloride Lotion (0.13%)             OTC           yes*                     granted
 Chlorhexidine Gluconate Lotion (4%)

                                           OTC / NDA            yes                     pending
        Chlorhexidine Gluconate (2%)
                   Pre-Surgical Prep             NDA            yes                     pending
Atopic Dermatitis / Super
Moisturizers
     Non-Steroidal Atopic Dermatitis
            Cream 1% Hyaluronic Acid   Rx / Cosmetic            yes                  technology
         Skin Protectant Lotion with
                      Allantoin (1%)             OTC            yes                  technology
       Super Moisturizer with Ectoin        Cosmetic            yes                  technology
        Urea Moisturizer (25% & 30%)        Cosmetic            yes                  technology
UVA / UVB Sunscreen
      Parsol 1789 - SPF 15 / 30 / 50
                              Lotion             OTC            yes                     pending
Tinosorb S - SPF 15 / 30 / 50 Lotion             OTC            yes                     pending
Other
         Scar Lotion with Onion Bulb        Cosmetic            yes                  technology
        Fragrance - Long Lasting Gel        Cosmetic            yes                  technology
  Long-lasting Sunless Tanner (2.5%,
                            5% & 9%)        Cosmetic            yes                  technology
              After Sun (Aloe) Cream        Cosmetic            yes                  technology

END OF CITATION FROM 10-Q

Licensing products is an important source of revenue for SKVI.

Invisicare technology produces a variety of prescription dermatology and over-the-counter skincare products along with hospital-related and consumer goods products that address a variety of medical conditions.

SKVI is active in terms a broad geographic range of licensing and in terms of product scope and numbers.

As SKVI increases its scope geographically and the number of products … it enhances shareholder value exponentially.

Licensed Technology Invisicare® Polymer Delivery Vehicles

Skinvisible licenses its patented Invisicare formulations to established developers and manufacturers of dermatology, cosmetic, skincare, medical, consumer goods and surgical products, both in over-the-counter and prescription formats.

Products in the Pipeline

Products in the pipeline are considered to be those which have been developed by Skinvisible in response to a variety of topical skin applications and product development opportunities identified both independently and in collaboration with established manufacturers and marketers.

These products have been successfully tested in-house to determine “proof of concept” stability, proven active agent activity and sustained release) and are currently ready to be licensed to established pharmaceutical, OTC, cosmetic or skincare manufacturers for commercialization. Regulatory approvals may be required for some products.

The tremendous pipeline evidences the incredible potential of SKVI.

Skinvisible’s Invisicare pipeline includes topical products for the following condition or use:

Acne
Topical Analgesics and First Aid
Anti-Aging
Anti-Fungal
Anti-Inflammatory
Antimicrobial Hand Sanitizing Lotions
Dermatitis/Moisturizers
Skin Cancer
UVA /UVB Sunscreens
Warts
Other: Scar Treatment/Long-Lasting Fragrances/ Wound Care/ Pre-Surgical Treatments/ Preventative Treatments
UVA/UVB Sunscreen

What SKVI brings to the table is a much longer lasting and more durable product than the competition.

Sunscreen

A key addition to the product portfolio in 2008 was a UVA/UVB sunscreen with Parsol 1789. Parsol 1789 is the most used UVA filter in sunscreens in the US and the only ingredient approved by the US FDA that is not proprietary. The Company’s studies indicate a minimum of eight hour photostability compared to the industry average of two hours. In addition, most sunscreens, even those that indicate they are water resistant, do not remain on the skin after swimming.

With Invisicare technology, sunscreens remain on the skin for 8 to 12 hours and resist wash-off and rub-off. For the international market, new sunscreens using a proprietary sunscreen UVA filter from CIBA Specialty Chemicals have been developed. While this ingredient is not yet approved for sale in the US, it is used internationally and the Company is working with sunscreen companies in Europe and Latin America on this new development.

DermaSafe Hand Sanitizer Lotion

DermSafe stays bound to the hands, even after frequent washings, for up to four hours while killing both bacteria and viruses. This is considered to be a real plus for doctors and nurses as they move from patient to patient.

The Company intends to begin marketing Chlorhexidine Hand Sanitizer Lotion “DermSafe” in Canada in the third quarter of 2009 based upon approval from Health Canada. The Company expects to file for US FDA approval with a marketing partner in 2009 for this unique product that is needed immediately in all healthcare settings from hospitals to nursing homes.

Acne Product

The company has signed an agreement with Panalab Internacional S.A. for their anti-acne product formulated with Adapalene (licensed territories – Argentina, Brazil and Chile).

The company signed an agreement with Embil Pharmaceutical Co. Ltd. for products formulated with the active ingredients Clindamycine HCL and Retinoic Acid (licensed territories countries in Eastern Europe and three in South East Asia.

License Agreements
Current licensees: JD Nelson with Safe4Hours®, DRJ Group with Stopain® and Sunless Beauty with Solerra® all remain focused on expanding their markets in the US and Solerra globally.

Two New Licensees for 2008
Two acne formulations made with adapalene for Panalab Internacional S.A. for the territory of Latin America. Panalab is a multi-national dermatology company headquartered in Panama with subsidiaries and partners in most Latin American countries. Under the terms of the agreement, Panalab will be responsible for filing and obtaining marketing approval in the countries they have licensed.

A research and development fee plus a licensing fee allocated as an upfront fee plus milestone payments. In addition, royalties based on revenues generated by the sale of the products will be received. According to the agreement, Panalab will have the right to manufacture, distribute, market, sell and promote the Adapalene formulations in the specified territory. Panalabs expect to be selling in their territory by late fall 2009.

License Agreements in Turkey:

In addition, two more prescription acne products (clindamycin and retinoic acid) were licensed to Embil Pharmaceuticals for Turkey, parts of Asia (Indonesia, Malaysia, and the Philippines) and Azerbaijan, Kazakhstan, Kyrgyzstan, Turkmenistan, and Uzbekistan. Embil is a multi-national dermatology company headquartered in Instanbul, Turkey with subsidiaries and partners in S.E. Asia.

Under the terms of the agreement, Embil will be responsible for filing and obtaining marketing approval in the countries they have licensed. A research and development fee plus a licensing fee allocated as an upfront fee plus milestone paymentshas been received. Royalties based on revenues generated by the sale of the products will also be received. According to the agreement, Embil will have the right to manufacture, distribute, market, sell and promote the Clindamycin HCL and Retinoic Acid formulations for acne in the specified territory.

Contact:

Skinvisible, Inc.
6320 Sandhill Road
Suite 10
Las Vegas, NV 89120
http://www.skinvisible.com
Phone: 702-433-7154

About Invisicare: Invisicare is Skinvisible’s patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. It is a combination of hydrophilic and hydrophobic polymers that hold active ingredients on the skin for extended periods of time resisting both wash off and perspiration. Invisicare can control the release of actives, reduce irritation and can eliminate some costly manufacturing processes. It is non-occlusive and allows for normal skin respiration while protecting against environmental irritants. www.invisicare.com

About Skinvisible Pharmaceuticals, Inc.: Skinvisible Pharmaceuticals is a research-and-development company whose primary business objective is to license its proprietary formulations with Invisicare to pharmaceutical and cosmeceutical companies as well as assisting companies in enhancing their existing skin care products. Skinvisible receives a combination of research and development fees, upfront license fees, and ongoing royalties for the life of the Invisicare patent. Skinvisible’s value also lies in its ability to continually generate new IP on dermatology and medical products formulated with Invisicare. www.skinvisible.com

Forward Looking Statements: This profile contains ‘forward looking’ statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10Q for the quarter ending March 30, 2009).

Pentony Enterprises LLC is STOCKGURU.COM, SHAREHOLDERVISION.COM and STREETRESEARCH.COM. 9555 Lebanon Road; Suite 103; Frisco, Texas 75035. (469) 252-3030. Disclosure: Pentony Enterprises LLC will be compensated 500,000 144 restricted common shares by the company for profile coverage for the period ending January 30, 2010. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

Share and Enjoy: